[Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma].
Hormonal therapy against prostatic carcinoma brings to osteoporotic change and alendronate is effective to suppress the change. Urinary NTX and serum ICTP are shown to be useful markers to react with hormonal therapy. But most of bone metabolic markers are not within normal range at the time of starting hormonal therapy. The program, which evaluate the effect of hormonal therapy against non-metastatic prostatic carcinoma, is strongly expected. And it is still a serious problem to be solved when we start, how to use, how long we use biphosphonates.
Kuroda
Isao
I
Department of Uro-oncolgy, International Medical Center, Saitama Medical University.
Ueno
Munehisa
M
D019386:Alendronate / Q000008:administration & dosage; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000652:urine*; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D024042:Collagen Type I / Q000652:urine; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000139:chemically induced* / Q000175:diagnosis* / Q000517:prevention & control; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides / Q000652:urine; D011347:Procollagen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D010446:Peptide Fragments; D010455:Peptides; D011347:Procollagen; C052929:collagen type I trimeric cross-linked peptide; D019386:Alendronate